Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALDX Aldeyra Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ALDX
Price (delayed)
$3.79
Market cap
$227M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.97
Enterprise value
$192.22M
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's
Highlights
The quick ratio is up by 16% since the previous quarter and by 2.6% year-on-year
The net income has plunged by 92% YoY and by 3.3% from the previous quarter
The company's EPS has shrunk by 90% YoY and by 3.2% QoQ
Key stats
What are the main financial stats of ALDX
Market
Valuations
Earnings
Shares outstanding
59.9M
Market cap
$227M
Enterprise value
$192.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$61.15M
Net income
-$57.7M
EBIT
-$55.79M
EBITDA
-$55.54M
Free cash flow
-$45.71M
Per share
Balance sheet
Liquidity
EPS
-$0.97
EPS diluted
-$0.97
Free cash flow per share
-$0.76
Book value per share
$1.07
Revenue per share
$0
TBVPS
$1.56
Total assets
$93.2M
Total liabilities
$29.6M
Debt
$15.57M
Equity
$63.6M
Working capital
$78.44M
Debt to equity
0.24
Current ratio
6.49
Quick ratio
6.3
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.3%
Return on equity
-72.6%
Return on invested capital
-122.9%
Return on capital employed
-70.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALDX stock price
How has the Aldeyra Therapeutics stock price performed over time
Intraday
-2.07%
1 week
24.26%
1 month
72.27%
1 year
11.47%
YTD
-24.05%
QTD
-34.09%
Financial performance
How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.15M
Net income
-$57.7M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 92% YoY and by 3.3% from the previous quarter
Aldeyra Therapeutics's operating income has shrunk by 73% YoY
Price vs fundamentals
How does ALDX's price correlate with its fundamentals
Growth
What is Aldeyra Therapeutics's growth rate over time
Valuation
What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
3.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 90% YoY and by 3.2% QoQ
ALDX's equity is down by 44% year-on-year and by 10% since the previous quarter
ALDX's price to book (P/B) is 23% more than its 5-year quarterly average of 2.9 but 6% less than its last 4 quarters average of 3.8
Efficiency
How efficient is Aldeyra Therapeutics business performance
The ROE has plunged by 194% YoY and by 20% from the previous quarter
The return on assets has dropped by 158% year-on-year and by 14% since the previous quarter
The return on invested capital has surged by 62% year-on-year and by 3% since the previous quarter
Dividends
What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALDX.
Financial health
How did Aldeyra Therapeutics financials performed over time
The total assets has declined by 34% year-on-year and by 11% since the previous quarter
The current ratio is up by 16% since the previous quarter
Aldeyra Therapeutics's debt is 76% lower than its equity
The company's debt to equity has surged by 71% YoY and by 9% QoQ
ALDX's equity is down by 44% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.